A Phase 2 interventional study of Hyperbaric oxygen at 1.5 ATA and Sham treatment in Persistent Post-concussive Syndrome and Concussion Post Syndrome, sponsored by Essentia Health. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Essentia Health · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 46th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 2, and was the 58th registered.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
Browse Post-Concussion Syndrome studies →15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18+
Neuroscience Group · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 20–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Median enrollment 40 across the 61 interventional studies, 90 across the 16 observational. Of the 51 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 77 have an industry lead sponsor. The 10 most frequent:
Essentia Health is the lead sponsor of 19 studies on the registry; none are open to participants now.
Essentia Health has 1 study filed under Post-Concussion Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Post-Concussion Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978571Children's Hospital of Orange CountyPercutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS) | 2026-12 |
| NCT07303933Penn State UniversityFemale Concussion Head Cooling | 2027-01-01 |
| NCT07044596University of Wisconsin, MadisonNon-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline | 2027-06 |
| NCT07732374Summit Hyperbarics and WellnessLong-Term Outcomes Following HBOT | 2027-06-18 |
| NCT04760899University of IowaCerebellar TDCS for SRPCS Treatment | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Persistent post-concussive symptoms (PPCS) are a source of significant burden among a subset of patients with concussion with prevalence rates previously reported between 11 - 82% based on timing of assessment, diagnostic criteria, or population under study.
Examples of persistent post-concussion symptoms include balance problems, headaches, fatigue, poor concentration, forgetfulness, anxiety, irritability, and sleep disturbance. Few proposed therapies have proved successful in the management of persistent post-concussion symptoms following mild traumatic brain injury.
The investigators will explore hyperbaric oxygen administered in a randomized sham-controlled clinical trial as an effective and tolerable treatment in improving neuropsychological status among adult patients with persistent post-concussive symptoms.
The overall hypothesis to be evaluated is that hyperbaric oxygen improves neuropsychological status and a serum concussion biomarker associated with PPCS.
This is a parallel, randomized, double-blinded and sham-controlled study. A total of 100 subjects will be randomly assigned to either an intervention arm: 50 participants exposed to > 99.9% oxygen at 1.5 atmosphere absolute for 60 minutes over 40 treatments or sham-treatment arm: 50 participants exposed to oxygen and pressure composition equivalent to breathing atmospheric air for 60 minutes over 40 treatments.
This study is designed to determine whether hyperbaric oxygen improves neuropsychological status and ameliorates symptoms in adults with persistent post-concussive symptoms (PPCS) following mild traumatic brain injury. It recruits from either military or civilian population; uses a validated screening tool - Repeatable battery for the assessment of neuropsychological status (RBANS)- used in dementia and other forms of brain injury not used hitherto, in previous randomized control trial that investigated the effectiveness of hyperbaric oxygen in the management of PPCS. It also includes a concssuon biomarker, as an objective secondary endpoint.
The study is based on repeated measure design. The study will describe and track changes in the outcomes of interest over time, and examine associations between measures within each participant and across certain participant characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
Drug: Hyperbaric oxygen at 1.5 ATA
Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
Drug: Sham treatment
Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
Also known as: 1.5 ATA
Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of "descent"
Also known as: 1.2 ATA then changed to 1.0 ATA
Changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
RBANS comprises 12 subtests that yield five age-adjusted Index scores, each measuring a distinct cognitive domain, plus a Total Scale score reflecting global cognitive functioning: Immediate Memory Index Visuospatial/Constructional Index Language Index Attention Index Delayed Memory Index Raw subtest scores are converted to age-normed standard scores, yielding five Index scores and a Total Scale score, each with a normative mean of 100, standard deviation of 15, and obtainable range of approximately 40 to 160. The Total Scale score is not a sum or average of the Index scores; the five Index scores are summed, and that sum is converted to a standard score on the same metric. For every Index and for the Total Scale score, higher values indicate better cognitive performance, and lower values indicate worse performance. All values reported are age-adjusted standard scores; the "3-12 Months" row is each participant's mean across the 13-week, 6-month, and 12-month assessments.
Time frame: 13-week, 6-month, 12-month
Serum Concentrations of GFAP, NfL, Total Tau, and UCH-L1 at Baseline and 13 Weeks Post-Treatment
Serum concentrations of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), total tau, and ubiquitin C-terminal hydrolase L1 (UCH-L1), quantified in a single batch using the Quanterix Simoa Neurology 4-Plex B assay. Laboratory personnel were blinded to treatment allocation.
Time frame: Baseline, 13-week
PSQI Global Score
Description (components): Pittsburgh Sleep Quality Index component scores. Each of the seven components is scored 0-3; higher scores indicate worse sleep. C1 = subjective sleep quality; C2 = sleep latency; C3 = sleep duration; C4 = habitual sleep efficiency (hours slept ÷ hours in bed × 100); C5 = sleep disturbances; C6 = use of sleep medication; C7 = daytime dysfunction. Description (global): PSQI global score, the sum of all seven component scores. Range 0-21; higher scores indicate worse sleep quality. A global score \>5 indicates poor sleep quality.
Time frame: Baseline, 13-week, 6-month, 12-month
Neurobehavioral Symptom Inventory Total Score
This is a validated self-report measure of post-concussion symptoms, grouped into 4 clusters (somatosensory, cognitive, affective, and vestibular). Neurobehavioral Symptom Inventory (NSI) is a 22-item symptom scale; participants will rate the severity of their symptoms in the last 2 weeks on a 5-point Likert scale (0=none, 1= mild, 2=moderate, 3=severe, 4=very severe). The NSI total score is a sum of the 22 items (range 0-88). Higher scores indicate more severe symptoms.
Time frame: Baseline, 13 week, 6 month, 12 month
PCL-C Total Score c(Civilian)
This is a 17-item validated self-report measure that assesses PTSD symptoms. It is further subcategorized into three clusters (reexperiencing, avoidance, hyperarousal). A total score and cluster scores can be obtained based on DSM-IV-TR criteria. Each item is rated 1-5; total score ranges 17 to 85. Higher scores indicate worse symptom burden.
Time frame: Baseline, 13 weeks, 6 months, 12 months
WHOQOL-BREF Psychological Domain Score
World Health Organization Quality of Life - BREF (WHOQOL-BREF), a 26-item self-report instrument yielding four domain scores. All four domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life. The psychological domain result is shown here.
Time frame: Baseline, 13 weeks, 6 months, 12 months
Participants were recruited from outpatient clinics and hospitals in North Dakota. Candidates were referred to the neurology clinic at Essentia Health, Fargo, ND, where the study neurologist confirmed a diagnosis of persistent post-concussive symptoms following mild TBI and assessed eligibility. Candidates willing to participate underwent further assessment by hyperbaric research staff to fitness to receive hyperbaric exposure. Written informed consent was obtained before formal enrollment
| Milestone | Mild Hyperbaric Oxygen (Intervention) | Placebo Comparator |
|---|---|---|
| Started | 9 | 11 |
| Did not receive allocated intervention | 1 | 3 |
| Completed | 8 | 8 |
| Not completed | 1 | 3 |
RBANS comprises 12 subtests that yield five age-adjusted Index scores, each measuring a distinct cognitive domain, plus a Total Scale score reflecting global cognitive functioning: Immediate Memory Index Visuospatial/Constructional Index Language Index Attention Index Delayed Memory Index Raw subtest scores are converted to age-normed standard scores, yielding five Index scores and a Total Scale score, each with a normative mean of 100, standard deviation of 15, and obtainable range of approximately 40 to 160. The Total Scale score is not a sum or average of the Index scores; the five Index scores are summed, and that sum is converted to a standard score on the same metric. For every Index and for the Total Scale score, higher values indicate better cognitive performance, and lower values indicate worse performance. All values reported are age-adjusted standard scores; the "3-12 Months" row is each participant's mean across the 13-week, 6-month, and 12-month assessments.
| Score on a scale | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| Mean value of Immediate Memory assessed at 13-week, 6-month, and 12-month | 105.41 ± 18.08 | 91.37 ± 17.16 |
| Mean value of Visuospatial/Constructional assessed at 13-week, 6-month, and 12-month | 101.50 ± 12.32 | 100.53 ± 15.70 |
| Mean value of Language assessed at 13-week, 6-month, and 12-month | 100.55 ± 8.48 | 100.26 ± 9.64 |
| Mean value of Attention assessed at 13-week, 6-month, and 12-month | 102.05 ± 10.97 | 96.89 ± 12.39 |
| Mean value of Delayed Memory assessed at 13-week, 6-month, and 12-month | 102.00 ± 16.50 | 96.47 ± 18.76 |
| Mean value of Total RBANS score assessed at 13-week, 6-month, and 12-month | 101.59 ± 12.60 | 98.11 ± 17.85 |
Serum concentrations of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), total tau, and ubiquitin C-terminal hydrolase L1 (UCH-L1), quantified in a single batch using the Quanterix Simoa Neurology 4-Plex B assay. Laboratory personnel were blinded to treatment allocation.
| pg/mL | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| GFAP, Baseline | 21.69 ± 16.14 | 10.19 ± 8.48 |
| GFAP, 13 Weeks | 14.10 ± 7.29 | 8.88 ± 6.86 |
| NfL, Baseline | 11.84 ± 7.83 | 8.54 ± 3.16 |
| NfL, 13 weeks | 12.13 ± 9.11 | 10.80 ± 8.42 |
| Total Tau, Baseline | 1.47 ± 0.40 | 1.49 ± 0.70 |
| Total Tau, 13 weeks | 1.58 ± 0.54 | 1.42 ± 0.88 |
| UCH-L1, Baseline | 156.66 ± 153.05 | 160.00 ± 44.01 |
| UCH-L1, 13 weeks | 114.29 ± 85.97 | 195.30 ± 155.23 |
Description (components): Pittsburgh Sleep Quality Index component scores. Each of the seven components is scored 0-3; higher scores indicate worse sleep. C1 = subjective sleep quality; C2 = sleep latency; C3 = sleep duration; C4 = habitual sleep efficiency (hours slept ÷ hours in bed × 100); C5 = sleep disturbances; C6 = use of sleep medication; C7 = daytime dysfunction. Description (global): PSQI global score, the sum of all seven component scores. Range 0-21; higher scores indicate worse sleep quality. A global score \>5 indicates poor sleep quality.
| Score on a scale | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| Baseline | 8.50 ± 2.65 | 11.71 ± 3.15 |
| 13-week | 9.38 ± 2.67 | 8.67 ± 3.72 |
| 6-month | 10.50 ± 4.17 | 8.50 ± 1.64 |
| 12-month | 9.33 ± 3.56 | 9.50 ± 3.21 |
This is a validated self-report measure of post-concussion symptoms, grouped into 4 clusters (somatosensory, cognitive, affective, and vestibular). Neurobehavioral Symptom Inventory (NSI) is a 22-item symptom scale; participants will rate the severity of their symptoms in the last 2 weeks on a 5-point Likert scale (0=none, 1= mild, 2=moderate, 3=severe, 4=very severe). The NSI total score is a sum of the 22 items (range 0-88). Higher scores indicate more severe symptoms.
| Score on a scale | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| Baseline | 34.13 ± 17.59 | 47.00 ± 12.18 |
| 13 weeks | 32.00 ± 14.16 | 37.86 ± 17.70 |
| 6 months | 25.00 ± 12.02 | 42.33 ± 15.19 |
| 12 months | 28.67 ± 9.09 | 42.17 ± 16.94 |
This is a 17-item validated self-report measure that assesses PTSD symptoms. It is further subcategorized into three clusters (reexperiencing, avoidance, hyperarousal). A total score and cluster scores can be obtained based on DSM-IV-TR criteria. Each item is rated 1-5; total score ranges 17 to 85. Higher scores indicate worse symptom burden.
| Score on a scale | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| Baseline | 43.88 ± 17.68 | 44.63 ± 13.23 |
| 13 weeks | 42.25 ± 17.11 | 40.07 ± 13.37 |
| 6 months | 42.13 ± 22.35 | 46.34 ± 11.28 |
| 12 months | 38.67 ± 18.49 | 42.67 ± 13.47 |
World Health Organization Quality of Life - BREF (WHOQOL-BREF), a 26-item self-report instrument yielding four domain scores. All four domain scores are transformed to a 0-100 scale. Higher scores indicate better quality of life. The psychological domain result is shown here.
| Score on a scale | Mild Hyperbaric Oxygen (Intervention) | Placebo Control |
|---|---|---|
| Baseline | 53.13 ± 14.92 | 45.83 ± 18.23 |
| 13 weeks | 58.33 ± 15.67 | 47.22 ± 16.44 |
| 6 months | 58.33 ± 17.23 | 48.61 ± 15.89 |
| 12 months | 57.64 ± 12.45 | 50.00 ± 15.22 |
Collected over From the first study intervention session, 40 sessions delivered on weekdays over approximately 8 weeks per participant, up to the final study assessment period at 18 months after completing the 40 sessions.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mild Hyperbaric Oxygen Treatment (Intervention) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Placebo Control | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Mild Hyperbaric Oxygen Treatment (Intervention) | Placebo Control |
|---|---|---|
| Middle ear barotraumaEar and labyrinth disorders | 4/8 | 1/8 |
| ClaustrophobiaGeneral disorders | 1/8 | 0/8 |
| Progression of underlying conditionNervous system disorders | 1/8 | 1/8 |
Baseline characteristics are reported for the 16 randomized participants who completed the baseline assessment and initiated their allocated study intervention. Four randomized participants (1 intervention, 3 placebo) did not receive the allocated intervention and did not contribute baseline data.
| Age, Continuous(years) | Mild Hyperbaric Oxygen | Placebo Control | Total |
|---|---|---|---|
| Mean | 48.88 ± 14.29 | 42.13 ± 10.60 | 45.50 ± 12.64 |
| Sex: Female, Male(Participants) | Mild Hyperbaric Oxygen | Placebo Control | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Mild Hyperbaric Oxygen | Placebo Control | Total |
|---|---|---|---|
| Race: White | 8 | 8 | 16 |
| Region of Enrollment(Participants) | Mild Hyperbaric Oxygen | Placebo Control | Total |
|---|---|---|---|
| United States | 8 | 8 | 16 |
| Time from injury(months) | Mild Hyperbaric Oxygen | Placebo Control | Total |
|---|---|---|---|
| Mean | 20.63 ± 14.03 | 15.13 ± 10.03 | 17.88 ± 12.12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The study protocol, statistical plan and consent form will be available on request. Data will be available on aggregate level; data will be deidentified, the full dataset and statistical code will be available upon request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 6 months after study completion and for 36 months
Access criteria: A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.
Ran from Jun 2022 to primary completion in Aug 2025, 37 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Essentia Health